Takeda enters into partnership with Quintiles and Covance

By Alexandria Pesic

- Last updated on GMT

Related tags Pharmacology Takeda Covance

Takeda Pharmaceuticals has joined the growing list of pharma companies to forge strategic deals with contract research organisations (CRO) by signing new deals with Covance and Quintiles.

Under the terms of the agreement, Takeda will work in close partnership with Quintiles and Covance in the execution of global development programs to support new therapeutic compounds.

Explaining the company's reasons for entering into the deal, Robert Ahlbrandt, senior vice president of global development operations for Takeda's pharmaceutical development division said: “Takeda is focused on growing its global drug development footprint, especially in Asia, while at the same time ensuring quality and increasing efficiency of our operations.”

The company says through these newly forged relationships it will move towards a fully virtual outsourcing model, combining its own expertise and capabilities with those of Quintiles and Covance in an attempt to improve both productivity, and its global growth prospects.

Our new strategic partnerships with Covance and Quintiles will improve the agility and productivity or our drug development activities, helping us to deliver innovative new medicines to patients globally,” ​said Ahlbrandt.

The agreement goes some way towards fulfilling Takeda's aim to have a “global program-level sourcing strategy” ​to help increase its operational efficiency. As a result of the agreement the company will have full access to the clinical development and central laboratory services of Quintiles and Covance, with both companies providing the Japanese firm with dedicated resources to supports its development pipeline.

Welcome boon

In other news, Takeda suffered a setback earlier this month relating to the obesity drug Contrave - developed in conjunction with Californian biotech company, Orexigen.

In a statement dated 1 Feb, 2011, Takeda announced that the US Food and Drug Administration (FDA) had raised concerns about the drug's “cardiovascular safety profile”​ when used long-term in a population of obese and overweight subjects, and had demanded further tests be conducted before granting approval.

Related news

Show more

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more